Seres Therapeutics, a biotechnology company, is expected to report a loss of ($1.49) per share for the fiscal year 2024, according to a forecast by Chardan Capital, a leading equity research firm. The consensus estimate for the company’s full-year earnings is ($1.06) per share.
Various analysts have been covering Seres Therapeutics MCRB and providing their insights. JPMorgan Chase & Co. recently initiated coverage on the company, assigning it a “neutral” rating with a target price of $7.00 per share. Canaccord Genuity Group also raised their price target on Seres Therapeutics from $11.00 to $15.00, giving it a “buy” rating. HC Wainwright reaffirmed a “buy” rating and set a $25.00 target price for the stock. Overall, the consensus rating for Seres Therapeutics is currently “Strong Buy,” with an average target price of $14.00, according to data from STA Research.
Despite the positive analyst coverage, Seres Therapeutics stock has experienced a decline of 4.4%. On Friday, the stock traded at $5.24, down $0.24 from its previous trading session. A total of 421,691 shares were exchanged, compared to the average volume of 2,020,249 shares. The stock’s fifty-day moving average price stands at $5.68, while the 200-day moving average price is $5.92. Seres Therapeutics has a market capitalization of $669.83 million and a price-to-earnings ratio of -2.34. The stock has a beta of 2.64, indicating high volatility. In the past year, its share price has ranged from a low of $2.50 to a high of $9.49.
Seres Therapeutics recently reported its quarterly earnings for the period ending on May 9th. The company posted an earnings per share (EPS) of ($0.57), in line with the consensus estimate. It recorded a negative return on equity of 548.64% and a negative net margin of 3,509.50%. The company’s revenue for the quarter was ($0.52) million, falling significantly short of analyst estimates of $1.58 million. In the same quarter of the previous year, Seres Therapeutics reported an EPS of ($0.61), indicating a slight improvement.
Several Analysts have made changes to their holdings in Seres Therapeutics. Flagship Pioneering Inc. increased its stake in the company by 60.8% during the third quarter and now owns 23,117,045 shares. FMR LLC also raised its stake by 1.2% in the first quarter, owning a total of 18,911,458 shares. Federated Hermes Inc. increased its stake by 2.9% in the third quarter, holding 18,499,136 shares. Vanguard Group Inc. raised its stake by 24.0% during the third quarter, now owning 6,610,856 shares. BlackRock Inc. also increased its stake by 9.4% during the same period and owns 6,300,350 shares. Institutional investors and hedge funds collectively hold 90.16% of Seres Therapeutics’ stock. Seres Therapeutics continues to face challenges as it forecasts a loss for the fiscal year 2024. Despite positive analyst ratings, the stock has experienced a decline, reflecting investor concerns.
MCRB Stock Analysis & Forecast
According to five analysts’ predictions, the average target price for Seres Therapeutics Inc stock over the next 12 months is estimated to be $11.25. The analysts have given Seres Therapeutics Inc an average rating of “Strong Buy.” However, Stock Target Advisor’s own analysis of the company suggests a bearish outlook, considering two positive signals and seven negative signals. As of the most recent closing, the stock price of Seres Therapeutics Inc was $5.13. Over the past week, the stock price has decreased by 13.20%, over the past month by 12.46%, but it has seen a positive change of 35.36% over the last year.
